AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lupin's Q1 profit rose 52% YoY to Rs 1,221 crore, driven by strong growth in the US and Indian markets. Sales increased to Rs 6,164 crore from Rs 5,514 crore in the year-ago period. The company's US sales grew 24% to Rs 2,404 crore. Lupin shares are in focus, with an average target price of Rs 2,230 and a 'Buy' rating from 37 analysts.
Lupin Limited, a prominent pharmaceutical company, reported a significant 52% year-on-year (YoY) growth in its consolidated profit after tax (PAT) for the June quarter, reaching Rs 1,221 crore. This robust performance was primarily driven by strong sales in both the United States and Indian markets. The company's total sales for the quarter stood at Rs 6,164 crore, up from Rs 5,514 crore in the year-ago period.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet